- Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423–432.
- Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (London, England). 2007;369(9573):1641–1657.
- Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42.
- Norgard BM, Nielsen J, Fonager K, et al. The incidence of ulcerative colitis (1995–2011) and Crohn's disease (1995-2012) – based on nationwide Danish registry data. J Crohns Colitis. 2014;8(10):1274–1280.
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (stride): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
- Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
- Bernklev T, Jahnsen J, Lygren I, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11(10):909–918.
- LeBlanc K, Mosli MH, Parker CE, et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015;(9):Cd008655.
- Travis S, Feagan BG, Peyrin-Biroulet L, et al. Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA. J Crohn Colitis. 2017;11(11):1317–1325.
- Probert CS, Dignass AU, Lindgren S, et al. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014;8(3):200–207.
- Bennebroek Evertsz F, Nieuwkerk PT, Stokkers PCF, et al. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis. 2013;7(11):890–900.
- The Danish Medicines Council. Laegemiddelrekommandation med dyre laegemidler til behandling af kroniske inflammatoriske tarmsygdomme. [cited 2018 Nov 15]. Available from: https://medicinraadet.dk/media/1robjtez/lmr_gastro_32_adlegacy.pdf
- Larsen L, Jensen MD, Larsen MD, et al. The Danish National Registry for biological therapy in inflammatory bowel disease. Clin Epidemiol. 2016;8:607–612.
- Sundhedsstyrelsen. Sundhedsstyrelsens specialevejledning for Intern medicin: gastroenterologi og hepatologi 1. juni 2017. 2017.
- Steering Committee for BIOIBD. BIOIBD · National årsrapport 2016–2017. The Danish Clinical Registries; [cited 2018 Nov 7]. Available from: www.rkkp.dk
- McDermott E, Keegan D, Byrne K, et al. The Short Health Scale: a valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. J Crohn Colitis. 2013;7(8):616–621.
- Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43(1):29–32.
- D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
- Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8(4):318–325.
- Park SK, Ko BM, Goong HJ, et al. Short health scale: a valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease. WJG. 2017;23(19):3530–3537.
- Hjortswang H, Jarnerot G, Curman B, et al. The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol. 2006;41(10):1196–1203.
- Kappelman MD, Long MD, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(8):1315–1323.
- Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005;100(2):355–361.
- Panes J, Domenech E, Aguas Peris M, et al. Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study. J Gastroenterol Hepatol. 2017;32(11):1818–1824.
- Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study . Inflamm Bowel Dis. 2005;11(5):488–496.
- Vaizey CJ, Gibson PR, Black CM, et al. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol. 2014;5(3):183–189.
Scandinavian Journal of Gastroenterology
Volume 55, 2020 - Issue 6
Original Article
Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy
Bjørn RasmussenResearch Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense C, Denmark; Correspondence[email protected]
http://orcid.org/0000-0003-2175-6563
http://orcid.org/0000-0003-2175-6563, , , &